Press Releases

• Current Use of FDA-Approved Pharmacotherapy for MS-Related Symptoms Is Low, Regardless of the High Need Reported by US Neurologists, According to a Recent BioTrends Report
  February 21, 2012

  
  

  Read More
• Current Use of FDA-Approved Pharmacotherapy for MS-Related Symptoms Is Low, Regardless of the High Need Reported by US Neurologists, According to a Recent BioTrends Report
  January 25, 2012

  
  

  Read More
• Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment Patterns Between DMA Brands and EU5 Countries Through Analysis of “Real World” DMA-Treated MS Patients
  January 23, 2012

  
  

  Read More
• Decision Resources Group to Bring its One-Day Oncology Seminar to San Francisco
  January 23, 2012

  Geared Toward Pharmaceutical and Biotech Executives, This One-Day Event Will Address Oncology Drug Market Drivers, Challenges and Opportunities

  Read More
• Despite No Current Approval of Janssen’s Zytiga in Asymptomatic/Minimally Symptomatic MCRPC, 31% of Surveyed Physicians Report Decreased Use of Dendreon’s Provenge Because Zytiga is Available for Later Lines of Treatment
  January 16, 2012

  
  

  Read More
• Despite Rapidly Adopting Molecular Screening for Xalkori, Medical Oncologists are Having Difficulty Finding Patients
  January 12, 2012

  BioTrends Research Group, LLC has released findings from the LaunchTrends^®: Xalkori report, which is tracking the launch of this new targeted therapy. The study finds that Pfizer’s Xalkori (crizotinib), which is indicated for patients with ALK-positive locally advanced or metastatic NSCLC, has a positive perception among Medical Oncologists but finding the appropriate patient can be difficult. Despite initial low Xalkori usage, Medical Oncologists intend to continue testing for the ALK translocation that Xalkori targets, as this therapy is viewed as a major advancement in the treatment of advanced NSCLC.
  

  Read More
• New Study of Chronic Kidney Disease Patients Finds that Treatment with Phosphate Binders and Active Vitamin D is Significantly Higher When Nephrologists Suspect Arterial Calcification
  December 28, 2011

  
  

  Read More
• New Report by BioTrends Explores the Unmet Need for Treatment Related to Proliferative and Non-Proliferative Glomerulonephritis
  December 27, 2011

  Results of a survey of 100 U.S. nephrologists suggest that the need for new therapies targeted at glomerulonephritis (GN) is extremely high, with only polycystic kidney disease having significantly higher unmet need.

  Read More
• While Clinicians’ Awareness of and Familiarity with Optimer/Cubist’s Dificid Has Increased Since Product Launch, Cost Continues to be the Main Barrier to its Use in Patients with CDAD According to Results from a LaunchTrends Institutional Study
  December 27, 2011

  Results from a survey fielded three months after commercial launch of Dificid (fidaxomicin) find that approximately half of clinicians have already prescribed Dificid to their Clostridium difficile-associated disease (CDAD) patients.

  Read More
• Incivek and Victrelis Usage as Part of Triple Therapy Hepatitis C Regimen is Emerging as the New Standard of Care for Genotype 1 Patients According to a Newly Released Report by BioTrends Research Group
  December 22, 2011

  Six months post-launch of Vertex’s Incivek (telapravir) and Merck/Roche’s Victrelis (boceprevir), specialists report a significant increase in usage of both products in their genotype 1 HCV patients compared to one month post-launch.

  Read More
Displaying results 1-10 (of 107)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >|